45
Participants
Start Date
October 31, 2008
Primary Completion Date
January 31, 2012
Study Completion Date
January 31, 2012
Lenalidomide
"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.~During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
Fludarabine
25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
Rituximab
"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.~Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
Medizinische Universitaet Innsbruck, Abtlg. f. Haematologie und Onkologie, Innsbruck
Landeskrankenhaus Feldkirch, Feldkirch
Krankenhaus d. Barmherzigen Schwestern Linz, Linz
Krankenhaus der Elisabethinen Linz GmbH, Linz
Krankenhaus der Stadt Linz, Linz
Universitaetsklinik f. Innere Medizin III, Salzburg
Klinikum Wels-Grieskirchen GmbH, Wels
Collaborators (1)
Celgene Corporation
INDUSTRY
Roche Pharma AG
INDUSTRY
Arbeitsgemeinschaft medikamentoese Tumortherapie
OTHER